131 related articles for article (PubMed ID: 28216213)
1. Expression of Cathepsin K in Skull Base Chordoma.
Tian K; Ma J; Wang L; Wang K; Li D; Hao S; Yang Y; Du J; Jia G; Zhang L; Wu Z; Zhang J
World Neurosurg; 2017 May; 101():396-404. PubMed ID: 28216213
[TBL] [Abstract][Full Text] [Related]
2. Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma.
Otani R; Mukasa A; Shin M; Omata M; Takayanagi S; Tanaka S; Ueki K; Saito N
J Neurosurg; 2018 May; 128(5):1428-1437. PubMed ID: 28753115
[TBL] [Abstract][Full Text] [Related]
3. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
[TBL] [Abstract][Full Text] [Related]
4. Predictive Value of Transforming Growth Factor-α and Ki-67 for the Prognosis of Skull Base Chordoma.
Zhang S; Bai J; Li M; Zhai Y; Wang S; Liu Q; Li C; Gui S; Zhang Y
World Neurosurg; 2019 Sep; 129():e199-e206. PubMed ID: 31125781
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Factors in Skull Base Chordoma: A Systematic Literature Review and Meta-Analysis.
Zou MX; Lv GH; Zhang QS; Wang SF; Li J; Wang XB
World Neurosurg; 2018 Jan; 109():307-327. PubMed ID: 29045855
[TBL] [Abstract][Full Text] [Related]
6. Whole-transcriptome analysis of chordoma of the skull base.
Bell D; Raza SM; Bell AH; Fuller GN; DeMonte F
Virchows Arch; 2016 Oct; 469(4):439-49. PubMed ID: 27401718
[TBL] [Abstract][Full Text] [Related]
7. Analysis of clinical factors and PDGFR-β in predicting prognosis of patients with clival chordoma.
Zhai Y; Bai J; Wang S; Gao H; Li M; Li C; Gui S; Zhang Y
J Neurosurg; 2018 Dec; 129(6):1429-1437. PubMed ID: 29303447
[TBL] [Abstract][Full Text] [Related]
8. Chordoma of the skull base: predictors of tumor recurrence.
Pallini R; Maira G; Pierconti F; Falchetti ML; Alvino E; Cimino-Reale G; Fernandez E; D'Ambrosio E; Larocca LM
J Neurosurg; 2003 Apr; 98(4):812-22. PubMed ID: 12691407
[TBL] [Abstract][Full Text] [Related]
9. Expression of hepatocyte growth factor and c-MET in skull base chordoma.
Naka T; Kuester D; Boltze C; Scheil-Bertram S; Samii A; Herold C; Ostertag H; Krueger S; Roessner A
Cancer; 2008 Jan; 112(1):104-10. PubMed ID: 17948912
[TBL] [Abstract][Full Text] [Related]
10. Skull base chordomas: clinical outcome in a consecutive series of 45 patients with long-term follow-up and evaluation of clinical and biological prognostic factors.
Boari N; Gagliardi F; Cavalli A; Gemma M; Ferrari L; Riva P; Mortini P
J Neurosurg; 2016 Aug; 125(2):450-60. PubMed ID: 26745472
[TBL] [Abstract][Full Text] [Related]
11. SNF5 as a prognostic factor in skull base chordoma.
Li M; Zhai Y; Bai J; Wang S; Gao H; Li C; Gui S; Du J; Zhang Y
J Neurooncol; 2018 Mar; 137(1):139-146. PubMed ID: 29222701
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological implications of TIM3
Zhou J; Jiang Y; Zhang H; Chen L; Luo P; Li L; Zhao J; Lv F; Zou D; Zhang Y; Jing Z
Cancer Immunol Immunother; 2019 Jul; 68(7):1157-1169. PubMed ID: 31197461
[TBL] [Abstract][Full Text] [Related]
13. Fascin expression in skull base chordoma: correlation with tumor recurrence and dura erosion.
Gao Z; Zhang Q; Kong F; Chen G; Li M; Guo H; Liang J; Bao Y; Ling F
Med Oncol; 2012 Dec; 29(4):2438-44. PubMed ID: 22351250
[TBL] [Abstract][Full Text] [Related]
14. Expression of cathepsin K in chordoma.
Haeckel C; Krueger S; Kuester D; Ostertag H; Samii M; Buehling F; Broemme D; Czerniak B; Roessner A
Hum Pathol; 2000 Jul; 31(7):834-40. PubMed ID: 10923921
[TBL] [Abstract][Full Text] [Related]
15. Genomic and transcriptomic characterization of skull base chordoma.
Sa JK; Lee IH; Hong SD; Kong DS; Nam DH
Oncotarget; 2017 Jan; 8(1):1321-1328. PubMed ID: 27901492
[TBL] [Abstract][Full Text] [Related]
16. T gene isoform expression pattern is significantly different between chordomas and notochords.
Wang K; Hu Q; Wang L; Chen W; Tian K; Cao C; Wu Z; Jia G; Zhang L; Zeng C; Zhang J
Biochem Biophys Res Commun; 2015 Nov; 467(2):261-7. PubMed ID: 26435504
[TBL] [Abstract][Full Text] [Related]
17. C-Cbl and Cbl-b expression in skull base chordomas is associated with tumor progression and poor prognosis.
Luo P; Wang X; Zhou J; Li L; Jing Z
Hum Pathol; 2018 Apr; 74():129-134. PubMed ID: 29317233
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics, immunohistochemistry, and outcomes of 77 patients with skull base chordomas.
Ouyang T; Zhang N; Zhang Y; Jiao J; Ren J; Huang T; Chen J
World Neurosurg; 2014; 81(5-6):790-7. PubMed ID: 23298670
[TBL] [Abstract][Full Text] [Related]
19. The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma.
Tosuner Z; Bozkurt SU; Kiliç T; Yilmaz B
Turk Patoloji Derg; 2017; 33(2):112-120. PubMed ID: 28272674
[TBL] [Abstract][Full Text] [Related]
20. Chordoma: Immunohistochemical Analysis of Brachury.
Sun HI; Guduk M; Gucyetmez B; Yapicier O; Pamir MN
Turk Neurosurg; 2018; 28(2):174-178. PubMed ID: 28094431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
